INTI · Inhibitor Therapeutics, Inc.
What's happening
- INTI is up 12.14% today, trading at $0.11. — Live quote
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-07-31. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +147.5%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -153.6%. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-09-18; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on INTI
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Operating income | -$618.6K | -$695.6K | -$741.2K | -$695.8K | -$674.6K | -$813.2K | -$585.1K | -$774.8K |
| Net income | -$613.9K | -$686.4K | -$712.2K | -$659.9K | -$632.8K | -$731.0K | -$501.7K | -$684.7K |
| EPS (diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (basic) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $637.2K | $1.4M | $2.5M | $3.1M | $3.9M | $4.5M | $5.7M | $6.5M |
| Total liabilities | $3.2M | $3.4M | $3.8M | $3.1M | $3.2M | $3.2M | $3.7M | $3.0M |
| Stockholders' equity | -$2.6M | -$2.0M | -$1.3M | $3.5K | $715.6K | $1.4M | $2.0M | $3.4M |
| Total current assets | $586.8K | $1.4M | $2.4M | $3.1M | $3.8M | $4.4M | $5.7M | $6.5M |
| Total current liabilities | $174.9K | $382.3K | $766.3K | $87.5K | $140.0K | $94.7K | $709.6K | $44.6K |
| Cash & equivalents | $515.8K | $1.3M | $2.4M | $3.0M | $3.7M | $4.3M | $5.6M | $6.4M |
| Other current assets | — | — | — | — | — | — | — | — |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Accounts payable | $139.1K | $319.8K | $51.5K | $19.6K | $106.2K | $36.7K | $15.9K | $1.7K |
| Accrued liabilities | $9.6K | $33.5K | $690.1K | $40.4K | $7.7K | $32.0K | $693.7K | $42.9K |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $17.4K | $17.3K | $17.3K | $17.3K | $17.3K | $17.2K | $17.2K | $17.2K |
| Retained earnings | -$56.7M | -$56.1M | -$55.4M | -$54.1M | -$53.4M | -$52.8M | -$52.1M | -$50.7M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$775.2K | -$1.1M | -$601.2K | -$761.2K | -$584.0K | -$1.3M | -$771.4K | -$720.4K |
| Financing cash flow | — | — | — | — | — | — | — | — |
| Share-based compensation | $33.0K | — | $0 | $0 | $23.4K | — | $0 | $0 |
| Dividends paid | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 |
| Operating income | -$3.4M | -$3.7M | -$3.4M | -$657.9K | -$325.4K |
| Net income | -$3.3M | -$3.3M | -$3.0M | $12.1M | -$298.6K |
| EPS (diluted) | $-0.02 | $-0.02 | $-0.02 | $0.03 | $0.00 |
| EPS (basic) | $-0.02 | $-0.02 | $-0.02 | $0.03 | $0.00 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $2.5M | $5.7M | $8.9M | $12.0M | $58.8K |
| Total liabilities | $3.8M | $3.7M | $3.7M | $3.7M | $3.7M |
| Stockholders' equity | -$1.3M | $2.0M | $5.3M | $8.3M | -$3.6M |
| Total current assets | $2.4M | $5.7M | $8.9M | $12.0M | $58.8K |
| Total current liabilities | $766.3K | $709.6K | $665.2K | $678.8K | $679.6K |
| Cash & equivalents | $2.4M | $5.6M | $8.8M | $12.0M | $30.6K |
| Other current assets | — | — | — | — | — |
| Other non-current assets | — | — | — | — | $0 |
| Accounts payable | $51.5K | $15.9K | $33.7K | $145.2K | $279.8K |
| Accrued liabilities | $690.1K | $693.7K | $631.4K | $122.6K | $53.0K |
| Other current liabilities | — | — | — | — | $53.0K |
| Common stock & paid-in capital | $17.3K | $17.2K | $17.2K | $17.2K | $37.7K |
| Retained earnings | -$55.4M | -$52.1M | -$48.8M | -$45.8M | -$57.7M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$3.2M | -$3.2M | -$2.7M | $11.7M | -$220.4K |
| Financing cash flow | — | — | -$411.0K | $180.0K | $176.0K |
| Share-based compensation | $23.4K | $40.2K | $13.8K | — | $38.0K |
| Dividends paid | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding INTI as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2021-01-15 to 2026-07-01
Recent transactions
- Most recent: Black Robe Capital LLC (10% owner) — Gift of 3,200,000 shares on 2026-07-01.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Black Robe Capital LLC | 10% owner | Gift | 2026-07-01 | 3,200,000 |
| Vasisht Niraj | Director | Grant / award | 2026-05-05 | 50,000 |
| OSMAN RONALD E | Director | Grant / award | 2026-05-04 | 50,000 |
| Yanez Michelle | Director | Grant / award | 2026-05-04 | 50,000 |
| SEARS SAMUEL P JR | Director | Grant / award | 2026-05-04 | 50,000 |
| ODONNELL FRANCIS E JR | Chief Executive Officer | Grant / award | 2026-05-04 | 50,000 |
| Jerman Michael Allen | Director | Grant / award | 2026-05-04 | 50,000 |
| MCNULTY JAMES A | See Remarks | Other acquisition/disposition | 2023-05-05 | 79,627,069 |
| Mayne Pharma Ventures Pty Ltd | 10% owner | Other acquisition/disposition | 2021-01-15 | 2,240,488 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-01 | Black Robe Capital LLC | 10% owner | Gift | 3,200,000 | $0.00 |
| 2026-05-05 | Vasisht Niraj | Director | Grant / award | 50,000 | $0.00 |
| 2026-05-04 | OSMAN RONALD E | Director | Grant / award | 50,000 | $0.00 |
| 2026-05-04 | Yanez Michelle | Director | Grant / award | 50,000 | $0.00 |
| 2026-05-04 | SEARS SAMUEL P JR | Director | Grant / award | 50,000 | $0.00 |
| 2026-05-04 | ODONNELL FRANCIS E JR | Chief Executive Officer | Grant / award | 50,000 | $0.00 |
| 2026-05-04 | Jerman Michael Allen | Director | Grant / award | 50,000 | $0.00 |
| 2025-04-01 | Vasisht Niraj | Director | Grant / award | 50,000 | $0.00 |
| 2025-04-01 | Yanez Michelle | Director | Grant / award | 50,000 | $0.00 |
| 2025-04-01 | SEARS SAMUEL P JR | Director | Grant / award | 50,000 | $0.00 |
| 2025-04-01 | OSMAN RONALD E | Director | Grant / award | 50,000 | $0.00 |
| 2025-04-01 | Jerman Michael Allen | Director | Grant / award | 50,000 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:30 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-18 | 8-K | 2026-09-15 | View on SEC.gov → |
| 2026-08-14 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-05-04 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-05-04 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-05-04 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-05-04 | View on SEC.gov → |
| 2026-06-24 | 4 | 2026-05-04 | View on SEC.gov → |
| 2026-06-01 | 4 | 2026-05-05 | View on SEC.gov → |
| 2026-05-15 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-04-01 | 8-K | 2026-04-01 | View on SEC.gov → |
| 2026-04-01 | 8-K | 2026-04-01 | View on SEC.gov → |
Recent news
Headlines about INTI (Inhibitor Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Inhibitor Therapeutics Highlights Key Developments and Reminds Stockholders of September 15 Annual Meeting
Yahoo Finance · 2026-09-08 -
Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome
Yahoo Finance · 2026-03-31 -
Basal Cell Nevus Syndrome Market Growth Accelerates with Novel Therapies and Clinical Developments | DelveInsight
Yahoo Finance · 2025-10-27 -
Inhibitor Therapeutics to start prostate cancer treatment trial
Seeking Alpha · 2019-11-25 -
HedgePath Pharmaeuticals: Mayne Pharma Tips Its Hand (While No Doubt Giddy With Excitement!)
Seeking Alpha · 2018-11-09 -
HedgePath Pharmaceuticals: Yikes! Tampa, We Have A Problem!
Seeking Alpha · 2018-10-26 -
HedgePath Pharmaceuticals: What To Expect Next?
Seeking Alpha · 2018-05-10 -
HedgePath Pharmaceuticals: Some Primary Concerns Addressed And Mitigated Through Mayne Pharma Deal
Seeking Alpha · 2018-01-12
No headlines in this category right now — try “All”.